![cover image](https://wikiwandv2-19431.kxcdn.com/_next/image?url=https://upload.wikimedia.org/wikipedia/commons/thumb/a/ad/Losmapimod.svg/640px-Losmapimod.svg.png&w=640&q=50)
Losmapimod
Chemical compound / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about Losmapimod?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Losmapimod (GW856553X) is an investigational drug being developed by Fulcrum Therapeutics for the treatment of facioscapulohumeral muscular dystrophy (FSHD); a phase III clinical trial is pending approval. Losmapimod selectively inhibits enzymes p38α/β mitogen-activated protein kinases (MAPKs), which are modulators of DUX4 expression and mediators of inflammation.[1]
Quick Facts Legal status, Identifiers ...
![]() | |
Legal status | |
---|---|
Legal status | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider |
|
UNII | |
KEGG |
|
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.158.124 ![]() |
Chemical and physical data | |
Formula | C22H26FN3O2 |
Molar mass | 383.467 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Close